MannKind Net Income 2006-2021 | MNKD

MannKind net income from 2006 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
MannKind Annual Net Income
(Millions of US $)
2020 $-57
2019 $-52
2018 $-87
2017 $-117
2016 $126
2015 $-368
2014 $-198
2013 $-191
2012 $-169
2011 $-161
2010 $-171
2009 $-220
2008 $-303
2007 $-293
2006 $-231
2005 $-114
MannKind Quarterly Net Income
(Millions of US $)
2021-09-30 $-4
2021-06-30 $-36
2021-03-31 $-13
2020-12-31 $-26
2020-09-30 $-11
2020-06-30 $-10
2020-03-31 $-9
2019-12-31 $-14
2019-09-30 $-10
2019-06-30 $-12
2019-03-31 $-15
2018-12-31 $-10
2018-09-30 $-24
2018-06-30 $-23
2018-03-31 $-30
2017-12-31 $-33
2017-09-30 $-33
2017-06-30 $-35
2017-03-31 $-16
2016-12-31 $54
2016-09-30 $127
2016-06-30 $-30
2016-03-31 $-25
2015-12-31 $-277
2015-09-30 $-32
2015-06-30 $-29
2015-03-31 $-31
2014-12-31 $-36
2014-09-30 $-37
2014-06-30 $-73
2014-03-31 $-52
2013-12-31 $-54
2013-09-30 $-51
2013-06-30 $-46
2013-03-31 $-41
2012-12-31 $-52
2012-09-30 $-43
2012-06-30 $-37
2012-03-31 $-38
2011-12-31 $-36
2011-09-30 $-38
2011-06-30 $-44
2011-03-31 $-42
2010-12-31 $-38
2010-09-30 $-45
2010-06-30 $-42
2010-03-31 $-45
2009-12-31 $-60
2009-09-30 $-46
2009-06-30 $-56
2009-03-31 $-59
2008-12-31 $-83
2008-09-30 $-68
2008-06-30 $-80
2008-03-31 $-71
2007-12-31 $-75
2007-09-30 $-73
2007-06-30 $-72
2007-03-31 $-73
2006-12-31 $-71
2006-09-30 $-61
2006-06-30 $-55
2006-03-31 $-44
2005-12-31 $-33
2005-09-30 $-32
2005-06-30 $-27
2005-03-31 $-22
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.985B $0.065B
Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69